Telo Genomics announced new clinical research showing its blood-based TELO-MRD test detects residual multiple myeloma cells more sensitively than traditional bone marrow tests like Adaptive clonoSEQ. The TELO-MRD liquid biopsy identifies circulating tumor cells and profiles their genetic instability in blood, offering a less invasive alternative to bone marrow biopsies. Early results from small studies suggest TELO-MRD could complement existing methods by detecting residual disease even when bone marrow tests are negative or inconclusive. The company plans further validation and aims to commercialize TELO-MRD by the end of 2027, potentially improving monitoring and treatment decisions for multiple myeloma patients.
Telo Genomics clinical research results provide context for health sector market activity. For readers following the health sector, here is Pluang's market snapshot as of Sep 29, 2026 14:01 WIB: out of 100 priced US health stocks, 38 rose and 51 fell. Notable movers include MESO at USD 14.51 with a -4.03% change, CLPT at USD 15.38 with a +3.71% change and 100% buy order activity, and ADPT at USD 28.40 with a -3.50% change and 100% buy order activity.
HBAR surged 24.38% following Hedera Council members joining NVIDIA’s Open Agent Safety Platform, strengthening ties with AI verification and enterprise infrastructure. This collaboration, including EQTY Lab’s use of NVIDIA GPUs, sparked a rapid incre...
Brady Corporation is rated Buy as it trades at a discount compared to its peers and discounted cash flow valuation. The company recently acquired Honeywell’s PSS business for $1.4 billion, making it the second largest player in the automatic identifi...
The cryptocurrency AAVE surged 9.31% within four hours to reach $163, extending its 24-hour gain to 10.07%. This price increase was accompanied by $140,000 in short liquidations on major exchanges like Binance, Bybit, and OKX, while no long liquidati...
On September 28, all four major crypto spot ETFs—Bitcoin, Ethereum, Solana, and XRP—recorded net inflows totaling about $65 million, highlighting growing institutional demand beyond Bitcoin alone. Bitcoin ETFs led with $31.07 million, followed by Eth...
Poolbeg Pharma has secured funding to complete its clinical trials through to the second quarter of 2028. The company is currently recruiting patients for its TOPICAL trial of POLB 001, a drug aimed at preventing cytokine release syndrome in cancer p...
